Analyst’s Estimates on Shares’ Price: Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) soared 1.35% during previous trade, a total of 9.26M shares exchanged hands compared with its average trading volume of 9.31M shares whereas its relative volume is 1.01. The stock has a market capitalization of $60.73B along with 1.47B outstanding shares. Stock’s intraday price range hit the peak level of $41.62 and touched the lowest level of $40.78.

Most recently Abbott Laboratories (NYSE:ABT)’s price target was revised on 01/06/17 and according to 13 analysts stock’s price will reach at $46.62 during 52 weeks with standard deviation of 2.62. Stock’s minimum price target estimates has been figured out at $41 while the maximum price target forecast is established at $50, if we look at the price target with an optimistic approach it has upside potential of 21% from its latest closing price of $41.29.

Historically, if we look at price target revisions, two weeks ago Abbott Laboratories (NYSE:ABT)’s price target was revised on 12/21/16 by the analysts, however the bullish price estimates of the stock set at $50 while the bearish estimates kept at $45 over the next one year. Stock’s 52-week target was retained at $47.50, the estimates indicates a standard deviation of 2.07.

While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 1.60. ABR value is precisely based on brokerage recommendations, where out of 15 brokerage recommendations 10 rate Abbott Laboratories (NYSE:ABT) stock a Strong Buy, 1 rate the stocks of the company a Buy, 4 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Most recently on 6/21/16 the stock of Abbott Laboratories (NYSE:ABT) upgraded by Edward Jones from Hold to Buy. However previously on 1/4/16 it was downgraded by Morgan Stanley from Overweight to Equal-Weight. A research note issued on 11/13/15 the stock was downgraded by Goldman from Buy to Neutral.

Abbott Laboratories (NYSE:ABT) performance over the past one year soared 3.93% whereas its year to date (YTD) performance indicated a bullish trend of 7.50%. During the last six months the stock slipped -1.56%. Quarterly performance of the company shows declining momentum of -4.48% while its last one month trend is positive with 6.57%. Stock’s weekly performance expressed up trend of 5.74%.

The company’s price sits 5.69% above from its 50-day moving average of $38.82 and 2.01% far from the stock’s 200-day moving average which is $41.12. Abbott Laboratories (NYSE:ABT)’s shares are currently trading -9.25% away from the 52-week high price of $45.50 and +16.84% far from the 52-week low price of $35.34.

According to consensus agreement of 13 analysts Abbott Laboratories (NYSE:ABT) will report earnings per share of $0.65 in their quarterly report and it is expected to announce the company’s results on 1/25/17 Before Market Open. For the current quarter the company has high EPS estimates of $0.66 in contradiction of low EPS estimates of $0.63. However a year ago for the same quarter the company has reported $0.62 EPS. Current year EPS projections for Abbott Laboratories (NYSE:ABT) set at $2.21 according to the sentiments of 17 analysts, while its lowest earnings estimates are $2.19 and highest earnings estimates are $2.23.

According to 12 analysts, Abbott Laboratories (NYSE:ABT)’s revenue estimates for the current quarter are $5.39B meanwhile the company has high revenue estimates of $5.44B in contradiction of low revenue estimates of $5.33B. For the current year the company’s revenue estimates are $20.9B compared to low analyst estimates of $20.85B and high estimates of $20.96B according to the projection of 15 analysts.

Analyst Viewpoints on Price Reaction History: Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) soared 0.16% during previous trade, a total of 7.98M shares exchanged hands compared with its average trading volume of 9.05M shares whereas its relative volume is 0.94. The stock has a market capitalization of $56.45B along with 1.47B outstanding shares. Stock’s intraday price range hit the peak level of $38.34 and touched the lowest level of $37.91.

Most recently Abbott Laboratories (NYSE:ABT)’s price target was revised on 12/21/16 and according to 13 analysts stock’s price will reach at $47.23 during 52 weeks with standard deviation of 2.07. Stock’s minimum price target estimates has been figured out at $43 while the maximum price target forecast is established at $50, if we look at the price target with an optimistic approach it has upside potential of 31% from its latest closing price of $38.29.

Historically, if we look at price target revisions, two weeks ago Abbott Laboratories (NYSE:ABT)’s price target was revised on 11/18/16 by the analysts, however the bullish price estimates of the stock set at $50 while the bearish estimates kept at $45 over the next one year. Stock’s 52-week target was retained at $48, the estimates indicates a standard deviation of 1.76.

While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 1.60. ABR value is precisely based on brokerage recommendations, where out of 15 brokerage recommendations 10 rate Abbott Laboratories (NYSE:ABT) stock a Strong Buy, 1 rate the stocks of the company a Buy, 4 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Most recently on 6/21/16 the stock of Abbott Laboratories (NYSE:ABT) upgraded by Edward Jones from Hold to Buy. However previously on 1/4/16 it was downgraded by Morgan Stanley from Overweight to Equal-Weight. A research note issued on 11/13/15 the stock was downgraded by Goldman from Buy to Neutral.

Abbott Laboratories (NYSE:ABT) performance over the past one year plunged -12.96% whereas its year to date (YTD) performance indicated a bearish trend of -12.59%. During the last six months the stock climbed 2.27%. Quarterly performance of the company shows declining momentum of -8.67% while its last one month trend is positive with 0.50%. Stock’s weekly performance expressed down trend of -1.64%.

The company’s price sits -2.81% below from its 50-day moving average of $39.01 and -5.48% below from the stock’s 200-day moving average which is $40.97. Abbott Laboratories (NYSE:ABT)’s shares are currently trading -15.85% away from the 52-week high price of $45.50 and +8.35% far from the 52-week low price of $35.34.

According to consensus agreement of 13 analysts Abbott Laboratories (NYSE:ABT) will report earnings per share of $0.65 in their quarterly report and it is expected to announce the company’s results on 1/25/17 Before Market Open. For the current quarter the company has high EPS estimates of $0.66 in contradiction of low EPS estimates of $0.64. However a year ago for the same quarter the company has reported $0.62 EPS. Current year EPS projections for Abbott Laboratories (NYSE:ABT) set at $2.21 according to the sentiments of 17 analysts, while its lowest earnings estimates are $2.19 and highest earnings estimates are $2.23.

According to 12 analysts, Abbott Laboratories (NYSE:ABT)’s revenue estimates for the current quarter are $5.41B meanwhile the company has high revenue estimates of $5.44B in contradiction of low revenue estimates of $5.35B. For the current year the company’s revenue estimates are $20.92B compared to low analyst estimates of $20.87B and high estimates of $20.96B according to the projection of 15 analysts.

Analysts Alert on Price Target: Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) soared 0.80% during previous trade, a total of 7.25M shares exchanged hands compared with its average trading volume of 8.45M shares whereas its relative volume is 0.87. The stock has a market capitalization of $55.11B along with 1.47B outstanding shares. Stock’s intraday price range hit the peak level of $38.08 and touched the lowest level of $37.60.

Most recently Abbott Laboratories (NYSE:ABT)’s price target was revised on 11/18/16 and according to 13 analysts stock’s price will reach at $47.38 during 52 weeks with standard deviation of 1.76. Stock’s minimum price target estimates has been figured out at $43 while the maximum price target forecast is established at $50, if we look at the price target with an optimistic approach it has upside potential of 25% from its latest closing price of $37.90.

Historically, if we look at price target revisions, two weeks ago Abbott Laboratories (NYSE:ABT)’s price target was revised on 11/14/16 by the analysts, however the bullish price estimates of the stock set at $50 while the bearish estimates kept at $45 over the next one year. Stock’s 52-week target was retained at $48.18, the estimates indicates a standard deviation of 1.78.

While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 1.60. ABR value is precisely based on brokerage recommendations, where out of 15 brokerage recommendations 10 rate Abbott Laboratories (NYSE:ABT) stock a Strong Buy, 1 rate the stocks of the company a Buy, 4 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Most recently on 6/21/16 the stock of Abbott Laboratories (NYSE:ABT) upgraded by Edward Jones from Hold to Buy. However previously on 1/4/16 it was downgraded by Morgan Stanley from Overweight to Equal-Weight. A research note issued on 11/13/15 the stock was downgraded by Goldman from Buy to Neutral.

Abbott Laboratories (NYSE:ABT) performance over the past one year plunged -12% whereas its year to date (YTD) performance indicated a bearish trend of -13.48%. During the last six months the stock slipped -2.03%. Quarterly performance of the company shows declining momentum of -9.38% while its last one month trend is negative with -2.07%. Stock’s weekly performance expressed down trend of -3.22%.

The company’s price sits -6.10% below from its 50-day moving average of $39.67 and -6.41% below from the stock’s 200-day moving average which is $40.96. Abbott Laboratories (NYSE:ABT)’s shares are currently trading -16.70% away from the 52-week high price of $45.50 and +7.25% far from the 52-week low price of $35.34.

According to consensus agreement of 13 analysts Abbott Laboratories (NYSE:ABT) will report earnings per share of $0.65 in their quarterly report and it is expected to announce the company’s results on 1/26/17. For the current quarter the company has high EPS estimates of $0.66 in contradiction of low EPS estimates of $0.64. However a year ago for the same quarter the company has reported $0.62 EPS. Current year EPS projections for Abbott Laboratories (NYSE:ABT) set at $2.21 according to the sentiments of 17 analysts, while its lowest earnings estimates are $2.19 and highest earnings estimates are $2.23.

According to 12 analysts, Abbott Laboratories (NYSE:ABT)’s revenue estimates for the current quarter are $5.41B meanwhile the company has high revenue estimates of $5.44B in contradiction of low revenue estimates of $5.35B. For the current year the company’s revenue estimates are $20.93B compared to low analyst estimates of $20.87B and high estimates of $20.96B according to the projection of 15 analysts.

Price Reaction History Under Analysts Radar: Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) plunged -2.34% during previous trade, a total of 11.19M shares exchanged hands compared with its average trading volume of 8.67M shares whereas its relative volume is 1.26. The stock has a market capitalization of $57.05B along with 1.47B outstanding shares. Stock’s intraday price range hit the peak level of $40.17 and touched the lowest level of $39.10.

Most recently Abbott Laboratories (NYSE:ABT)’s price target was revised on 11/11/16 and according to 13 analysts stock’s price will reach at $47.38 during 52 weeks with standard deviation of 1.78. Stock’s minimum price target estimates has been figured out at $43 while the maximum price target forecast is established at $50, if we look at the price target with an optimistic approach it has upside potential of 25% from its latest closing price of $39.20.

Historically, if we look at price target revisions, two weeks ago Abbott Laboratories (NYSE:ABT)’s price target was revised on 10/20/16 by the analysts, however the bullish price estimates of the stock set at $50 while the bearish estimates kept at $45 over the next one year. Stock’s 52-week target was retained at $48.59, the estimates indicates a standard deviation of 1.46.

While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 1.60. ABR value is precisely based on brokerage recommendations, where out of 15 brokerage recommendations 10 rate Abbott Laboratories (NYSE:ABT) stock a Strong Buy, 1 rate the stocks of the company a Buy, 4 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Most recently on 6/21/16 the stock of Abbott Laboratories (NYSE:ABT) upgraded by Edward Jones from Hold to Buy. However previously on 1/4/16 it was downgraded by Morgan Stanley from Overweight to Equal-Weight. A research note issued on 11/13/15 the stock was downgraded by Goldman from Buy to Neutral.

Abbott Laboratories (NYSE:ABT) performance over the past one year plunged -8.58% whereas its year to date (YTD) performance indicated a bearish trend of -10.52%. During the last six months the stock climbed 5.26%. Quarterly performance of the company shows declining momentum of -12.18% while its last one month trend is negative with -3.90%. Stock’s weekly performance expressed down trend of -1.66%.

The company’s price sits -4.22% below from its 50-day moving average of $40.83 and -2.87% below from the stock’s 200-day moving average which is $40.92. Abbott Laboratories (NYSE:ABT)’s shares are currently trading -13.85% away from the 52-week high price of $45.50 and +10.93% far from the 52-week low price of $35.34.

According to consensus agreement of 13 analysts Abbott Laboratories (NYSE:ABT) will report earnings per share of $0.65 in their quarterly report and it is expected to announce the company’s results on 1/26/17. For the current quarter the company has high EPS estimates of $0.66 in contradiction of low EPS estimates of $0.64. However a year ago for the same quarter the company has reported $0.62 EPS. Current year EPS projections for Abbott Laboratories (NYSE:ABT) set at $2.21 according to the sentiments of 17 analysts, while its lowest earnings estimates are $2.19 and highest earnings estimates are $2.23.

According to 12 analysts, Abbott Laboratories (NYSE:ABT)’s revenue estimates for the current quarter are $5.41B meanwhile the company has high revenue estimates of $5.44B in contradiction of low revenue estimates of $5.35B. For the current year the company’s revenue estimates are $20.93B compared to low analyst estimates of $20.87B and high estimates of $20.96B according to the projection of 15 analysts.

Stock to Watch for Earnings: Abbott Laboratories (NYSE:ABT)

Shares of Abbott Laboratories (NYSE:ABT) fell -2.82% to reach at $40.01 during previous trading session. The company has experienced volume of 19.30M shares while on average the company has a capacity of trading 8.03M share.

Abbott Laboratories (NYSE:ABT) on October 19, 2016 announced financial results for the third quarter ended Sept. 30, 2016.

  • Third-quarter worldwide sales of $5.3 billion increased 2.9 percent on a reported basis and 4.0 percent on an operational basis.
  • Reported diluted EPS from continuing operations under GAAP was a $(0.24) loss in the third quarter, primarily due to an adjustment of $(0.66) per share associated with Abbott’s equity investment in Mylan to reflect Mylan’s share price as of Sept. 30, 2016. Excluding specified items, adjusted diluted EPS from continuing operations was $0.59 in the third quarter, at the high end of the previous guidance range.
  • Abbott adjusted its full-year 2016 EPS guidance for continuing operations under GAAP to $0.59 to $0.61, and narrowed and raised at the mid-point its full-year 2016 adjusted EPS for continuing operations to $2.19 to $2.21, exceeding its initial guidance for the year.
  • In the third quarter, Abbott received U.S. FDA approval for its FreeStyle Libre Pro system, a revolutionary continuous glucose monitoring system for healthcare professionals to use with their patients with diabetes; submitted for U.S. regulatory approval a consumer version of FreeStyle Libre, to be used by people with diabetes to self-monitor glucose levels; received U.S. FDA approval for AbsorbTM, the only fully dissolving heart stent; and received U.S. FDA approval for TECNIS Symfony intraocular lenses for the treatment of cataracts, the first and only extended depth of focus lenses for people with cataracts.
  • On Sept. 16, 2016, Abbott announced the sale of Abbott Medical Optics, its vision care business, to Johnson & Johnson for $4.325 billion. This transaction aligns with Abbott’s shaping of its portfolio, which has recently focused on developing leadership positions in cardiovascular devices and expanding diagnostics. The transaction is expected to close in the first quarter of 2017 and is subject to customary closing conditions, including regulatory approvals.

Abbott Laboratories (NYSE:ABT) holds the market capitalization of $59.65B along with 1.47B outstanding shares. During the last trade, stock’s minimum price has been reached out at $39.94 while the maximum trading price moved at $41.38. Currently the stock price is moving -12.07% off from the highest level of twelve months and +13.22% above from twelve months low. Abbott Laboratories (NYSE:ABT) marked 52-week highest price level of $45.50 on 11/20/15 and 52-week lowest price level of $35.34 on 01/28/16. For the stock, price target value has been calculated at $47.88 based on calls of 13 experts. Stock’s minimum price target estimates has been figured out at $45.00 while the maximum price target forecast is established at $50.00.

As of current trade, Abbott Laboratories (NYSE:ABT) has shown weekly downbeat performance of -2.37%. Its six months performance indicated a bearish movement while its yearly performance reflected a negative trend of -1.73%. Year-to-date (YTD) performance of the stock illustrate downbeat trend of -8.67%. Shares of Abbott Laboratories (NYSE:ABT) currently have an ABR of 1.60, derived from a total of 15 opinions. The company’s price sits -5.44% below from its 50-day moving average of $41.75 and -0.80% below from the stock’s 200-day moving average of $41.36. The company has Relative Strength Index (RSI 14) of 36.34 along with Average True Range (ATR 14) of 0.85. Its weekly and monthly volatility is 2.15%, 1.93% respectively. The company’s beta value is at 1.35.

Abbott Laboratories (NYSE:ABT) currently has a PEG ratio of 3.24 where as its P/E ratio is 30.71. The company’s price to sales ratio for trailing twelve months is 2.87 and price to book ratio for most recent quarter is 2.85, whereas price to cash per share for the most recent quarter is 13.31. Abbott Laboratories (NYSE:ABT)’s price to free cash flow for trailing twelve months is 292.52. Its quick ratio for most recent quarter is 1.20 along with current ratio for most recent quarter of 1.50. Total debt to equity ratio of the company for most recent quarter is 0.41 whereas long term debt to equity ratio for most recent quarter is 0.29. Abbott Laboratories (NYSE:ABT) has a Return on Assets of 5.60%. The company currently has a Return on Equity of 10.90% and Return on Investment of 7.70%.

Stock in Queue: Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) share price plunged -5.38% or -2.34 points to reach at $41.16 during previous trading session. The stock’s price fluctuated within the range of $41.-02 – $43.27 during previous trading session. A total of 23.90M shares exchanged hands, whereas the company’s average trading volume stands at 7.90M shares. Abbott Laboratories (NYSE:ABT) has a market capitalization of $61.25B and most recently 1.47B outstanding shares have been calculated.

In terms of market analysis and trading signals, RSI moving above the horizontal 30 reference level is viewed as a bullish indicator, while the RSI moving below the horizontal 70 reference level is seen to be a bearish indicator. Movements above 70 are interpreted as indicating overbought conditions; conversely, movements under 30 reflect oversold conditions.

Relative strength index (RSI-14) for Abbott Laboratories (NYSE:ABT) is at 39.96.

According to sentiments of 8 analysts the mean estimates of short term price target for the company’s stock is marked at $7.09. The most optimistic analyst sees the stock reaching $11 while the most conventional predicts the target price at $4.93.

The consensus mean EPS for the current quarter is at $0.02 derived from a total of 6 estimates. According to analysts minimum EPS for the current quarter is expected at $-0.01 and can go high up to $0.11. However a year ago during same quarter Abbott Laboratories (NYSE:ABT) reported $0.02 EPS.

For the upcoming quarter, initial predictions are anticipating that the company will post earnings of $0.01 per share according to consensus of 6 analysts.

According to sentiments of 6 analysts the company is expected to report revenues of $22.51M for the current quarter. Bearish revenue estimates established at $22.02M while the bullish revenue forecast has been figured out at $22.9M.

In terms of Buy/Sell recommendations, analysts have a consensus rating of 1.89 on the shares of Abbott Laboratories (NYSE:ABT). Out of rating recommendations 7 have given the stock a Buy while 6 recommend the stock as Outperform. 5 have given the stock a Hold rating, 0 as Underperform and 0 as Sell.

On technical side, moving averages may help to distinguish direction of tendencies, and they might also be used to set levels of sustenance and resistance. Abbott Laboratories (NYSE:ABT)’s distance from 20 day simple moving average is -2.10% whereas its distance from 50 day simple moving average is -4.39% along with 1.19% distance from 200 day simple moving average.

An important factor to consider when evaluating a stock’s current and future value are the 52 week price high and low levels. Abbott Laboratories (NYSE:ABT) shares were trading -10.11% below from the 52-week high mark of $45.79 and 15.74% above from the 52-week bottom of $35.56 The stock hit its 52-week high price on 11/20/15, and 52-week low price on 1/28/16.

When we have a peek on stock’s historical trends we come to know that, the stock has slipped -2.23% in the past one week and plunged -0.63% during previous one month drive, the stock went down -1.93% during past quarter. In the last six months the stock’s performance fell -4.47% while yearly performance of the company advanced 1.45%.The company’s year to date (YTD) performance is at -6.64%.

While taking a glance at financials, we can look at a number of key indicators. Abbott Laboratories (NYSE:ABT) has a Return on Assets (ROA) of 5.60%. The company currently has a Return on Equity (ROE) of 10.90% and a Return on Investment (ROI) of 7.70%. Average true range (ATR-14) of the company sets at 0.84, along with its weekly and monthly volatility of 2.29%, 1.82% respectively. Beta value of the stock stands at 1.34.

The company’s price to free cash flow for trailing twelve months is 299.53. Its quick ratio for most recent quarter is 1.20 along with current ratio for most recent quarter of 1.50. Total debt to equity ratio of the company for most recent quarter is 0.41 whereas long term debt to equity ratio for most recent quarter is 0.29.

Have a Glance at Gap Inc (NYSE:GPS), Abbott Laboratories (NYSE:ABT)

Gap Inc (NYSE:GPS) share price went down -2.57% or -0.63 points to reach at $23.92 during the course of previous trade. The stock traded in the range of $23.60 – $24.35 during its most recent trading session. The stock has total market worth of $9.28B and it has total of 398.00M outstanding shares. Relative strength index (RSI-14) for Gap Inc (NYSE:GPS) is at 39.82.

Historically the stock has slipped -9.67% in the past week and plunged -5.08% in the last four weeks, the stock illustrate that its three months performance stands at 26.94% while its year to date performance is at -17.21%. Stock’s price oscillated from $17.00 to $33.18 during past twelve months. The stock is now trading at a distance of -6.68% from SMA-20. The stock is presently trading -1.04% below from its SMA-50. In the current trading session, the stock’s price moved -0.13% below from its SMA-200. If we take a look on its volatility, 3.03 percent was seen in a week and for the month it was 2.54 percent. Stock’s beta value stands at 1.25 and its ATR value is at 0.75.

Gap Inc (NYSE:GPS) on September 02, 2016 announced that Art Peck, chief executive officer of the company, will participate in Goldman Sachs’ 23rd Annual Global Retailing Conference in New York City on September 7, 2016.

A live webcast of Mr. Peck’s participation in the conference will be accessible from www.gapinc.com/investors beginning at approximately 9:35 a.m. ET on September 7, 2016. An archive of the webcast presentation will be available for 90 days.

Abbott Laboratories (NYSE:ABT) share price slipped -0.50% or -0.21 points to reach at $42.09 during previous trading session. Stock’s price oscillated between $41.89 and $42.45 for intra-day trading. Relative strength index (RSI-14) for Abbott Laboratories (NYSE:ABT) is at 34.71. It has total market capitalization of $61.56B.

Historically the stock has slipped -2.07% in the past week and plunged -6.07% in the last four weeks, the stock illustrate that its three months performance stands at 8.12% while its year to date performance is at -4.53%. The stock hit the peak price level of one year at $46.38 and touched the minimum level of $36.00. Shares are trading -8.08% off from the 52-week high price and +18.36% above from the 52-week bottom price level. The stock is now trading at a distance of -4.46% from SMA-20. The stock is presently trading -1.41% below from its SMA-50. In the current trading session, the stock’s price moved 2.71% above from its SMA-200. The company has a Return on Assets of 5.60%. The company currently has a Return on Equity of 10.90% and a Return on Investment of 7.70%.

Abbott Laboratories (NYSE:ABT) on August 24, 2016 reported it will present at the Wells Fargo 2016 Healthcare Conference on Wednesday, Sept. 7, 2016. Brian Yoor, senior vice president, finance and chief financial officer, will present at 7:45 a.m. Central time.

Trending Stocks Update: Abbott Laboratories (NYSE:ABT), Regions Financial Corp (NYSE:RF)

Abbott Laboratories (NYSE:ABT) share price went up 0.33% or +0.14 points to reach at $42.98 during the course of previous trade. The stock traded in the range of $42.09 – $43.28 during its most recent trading session. The stock has total market worth of $63.39B and it has total of 1.47B outstanding shares. Relative strength index (RSI-14) for Abbott Laboratories (NYSE:ABT) is at 43.48.

Historically the stock has slipped -2.85% in the past week and plunged -3.31% in the last four weeks, the stock illustrate that its three months performance stands at 10.04% while its year to date performance is at -2.51%. Stock’s price oscillated from $36.00 to $46.63 during past twelve months. The stock is now trading at a distance of -3.69% from SMA-20. The stock is presently trading 1.89% above from its SMA-50. In the current trading session, the stock’s price moved 4.80% above from its SMA-200. If we take a look on its volatility, 2.36 percent was seen in a week and for the month it was 1.47 percent. Stock’s beta value stands at 1.13 and its ATR value is at 0.72.

Abbott Laboratories (NYSE:ABT) on August 24, 2016 reported it will present at the Wells Fargo 2016 Healthcare Conference on Wednesday, Sept. 7, 2016. Brian Yoor, senior vice president, finance and chief financial officer, will present at 7:45 a.m. Central time.

Regions Financial Corp (NYSE:RF) share price rose 1.45% or +0.14 points to reach at $9.79 during previous trading session. Stock’s price oscillated between $9.65 and $9.87 for intra-day trading. Relative strength index (RSI-14) for Regions Financial Corp (NYSE:RF) is at 70.89. It has total market capitalization of $12.47B.

Historically the stock has climbed 1.03% in the past week and soared 6.88% in the last four weeks, the stock illustrate that its three months performance stands at -0.15% while its year to date performance is at 3.43%. The stock hit the peak price level of one year at $10.28 and touched the minimum level of $7.00. Shares are trading -2.81% off from the 52-week high price and +41.85% above from the 52-week bottom price level. The stock is now trading at a distance of 4.32% from SMA-20. The stock is presently trading 8.47% above from its SMA-50. In the current trading session, the stock’s price moved 11.00% above from its SMA-200. The company has a Return on Assets of 0.80%. The company currently has a Return on Equity of 6.30% and a Return on Investment of 13.70%.

In response to unprecedented flooding in several South Louisiana parishes, Regions Financial Corp (NYSE:RF) on August 16, 2016 announced the company will donate $25,000 to the American National Red Cross Disaster Relief Fund.

Regions will accept financial donations for the American National Red Cross Disaster Relief Fund at all Regions branch locations throughout the South, Midwest and Texas. Customers and concerned individuals can visit any Regions branch location to make a donation; simply ask for the American National Red Cross Disaster Relief Fund account.

Regions is also offering a variety of financial services to help people in South Louisiana as flood recovery gets underway. Special offers include:

  • Unsecured personal lines of credit to help with flood recovery
  • Penalty-free withdrawals from CDs
  • Personal and business loan payment deferrals
  • A dedicated team to assist customers who have difficulties making payments on loans, lines of credit or credit cards
  • Special discounts available for new business term loans

Customers, individuals and business owners can also access the Regions Disaster Resource Center housed on regions.com to learn how Regions can assist individuals and businesses that face financial challenges. The Disaster Resource Center provides a clearinghouse of information and tools, available 24 hours a day, seven days a week. Resources include important contact information, articles, a financial checklist, details on Regions’ assistance programs, and links to relevant outside agencies and organizations.

Analyst Perspectives on Price Target History: Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) plunged -0.16% during previous trade, a total of 6.51M shares exchanged hands compared with its average trading volume of 64.75M shares whereas its relative volume is 0.65. The stock has a market capitalization of $64.75B along with 1.47B outstanding shares. Stock’s intraday price range hit the peak level of $44.36 and touched the lowest level of $43.79.

Most recently Abbott Laboratories (NYSE:ABT)’s price target was revised on 08/04/16 and according to 14 analysts stock’s price will reach at $48.00 during 52 weeks with standard deviation of 1.78. Stock’s minimum price target estimates has been figured out at $45.00 while the maximum price target forecast is established at $52.00, if we look at the price target with an optimistic approach it has upside potential of 18% from its latest closing price of $44.17.

Historically, if we look at price target revisions, three weeks ago Abbott Laboratories (NYSE:ABT)’s price target was revised on 07/25/16 by the analysts, however the bullish price estimates of the stock set at $50.00 while the bearish estimates kept at $45.00 over the next one year. Stock’s 52-week target was retained at $48.36, the estimates indicates a standard deviation of 1.36.

While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 1.60. ABR value is precisely based on brokerage recommendations, where out of 15 brokerage recommendations 10 rate Abbott Laboratories (NYSE:ABT) stock a Strong Buy, 1 rate the stocks of the company a Buy, 4 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Most recently on 6/21/2016 the stock of Abbott Laboratories (NYSE:ABT) upgraded by Edward Jones from Hold to Buy. However previously on 1/4/2016 it was downgraded by Morgan Stanley from Overweight to Equal-Weight. A research note issued on 11/13/2015 the stock was downgraded by Goldman from Buy to Neutral.

Abbott Laboratories (NYSE:ABT) performance over the past one year advanced 0.19%, during the last six months the stock rose -3.97%. Quarterly performance of the company shows optimistic momentum of 16.47% while its last one month trend is positive with 2.32%. Stock’s weekly 18.92 expressed down trend of -2.17%.

The company’s price sits 5.90% above from its 50-day moving average of $43.57 and 7.66% far from the stock’s 200-day moving average which is $40.63. Abbott Laboratories (NYSE:ABT)’s shares are currently trading -8.59% away from the 52-week high price of $48.32 and +24.20% far from the 52-week low price of $35.56.

According to consensus agreement of 16 analysts Abbott Laboratories (NYSE:ABT) will report earnings per share of $0.58 in their quarterly report and it is expected to announce the company’s results on 10/19/16. For the current quarter the company has high EPS estimates of $0.61 in contradiction of low EPS estimates of $0.57. However a year ago for the same quarter the company has reported $0.54 EPS. Current year EPS projections for Abbott Laboratories (NYSE:ABT) are set at $2.2 according to the sentiments of 23 analysts, while its lowest earnings estimates are $2.16 and highest earnings estimates are $2.23.

According to 15 analysts, Abbott Laboratories (NYSE:ABT)’s revenue estimates for the current quarter are $5.29 billion meanwhile the company has high revenue estimates of $5.34 billion in contradiction of low revenue estimates of $5.16 billion. For the current year the company’s revenue estimates are $20.94 billion compared to low analyst estimates of $20.63 billion and high estimates of $21.08 billion according to the projection of 18 analysts.

Watch List: Abbott Laboratories (NYSE:ABT), Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Abbott Laboratories (NYSE:ABT) went down -0.27% or -0.12 points to reach at $44.24 during the course of previous trade. The stock traded in the range of $43.65 – $44.31 during its most recent trading session. The stock has total market worth of $64.86B and it has total of 1.47B outstanding shares. Relative strength index (RSI-14) for Abbott Laboratories (NYSE:ABT) is at 56.74.

Historically the stock has slipped -1.78% in the past week and soared 2.79% in the last four weeks, the stock illustrate that its three months performance stands at 18.38% while its year to date performance is at 0.35%. Stock’s price oscillated from $36.00 to $48.43 during past twelve months. The stock is now trading at a distance of -0.87% from SMA-20. The stock is presently trading 6.35% above from its SMA-50. In the current trading session, the stock’s price moved 7.82% above from its SMA-200. If we take a look on its volatility, 1.12 percent was seen in a week and for the month it was 1.24 percent. Stock’s beta value stands at 1.12 and its ATR value is at 0.56.

Abbott Laboratories (NYSE:ABT) on August 9, 2016 announced the introduction of Alinity™, its harmonized family of next-generation systems across immunoassay, clinical chemistry, point of care, hematology, blood and plasma screening and molecular diagnostics. Each Alinity platform will include a number of features to help institutions, clinicians and laboratorians better navigate through a pressure-packed health care environment.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) slipped -5.05% or -0.21 points in order to take the company’s stock at the price of $3.95 during previous trading session. Stock’s price oscillated between $3.84 and $4.15 for intra-day trading. Relative strength index (RSI-14) for Celldex Therapeutics, Inc. (NASDAQ:CLDX) is at 32.96. It has total market capitalization of $377.11B.

Historically the stock has slipped -11.43% in the past week and plunged -16.67% in the last four weeks, the stock illustrate that its three months performance stands at -1.99% while its year to date performance is at -74.81%. The stock hit the peak price level of one year at $18.62 and touched the minimum level of $2.96. Shares are trading -78.79% off from the 52-week high price and +33.45% above from the 52-week bottom price level. The stock is now trading at a distance of -13.29% from SMA-20. The stock is presently trading -12.06% below from its SMA-50. In the current trading session, the stock’s price moved -48.08% below from its SMA-200. The company has a Return on Assets of -41.60%. The company currently has a Return on Equity of -47.60%.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) on August 11, 2016 announced that the Company has promoted Elizabeth Crowley to the newly created position of Senior Vice President, Chief Product Development Officer. Ms. Crowley was previously Senior Vice President of Product Development of Celldex and brings almost 25 years of industry experience where she was responsible for leading the execution of multiple successful drug development programs.

Ms. Crowley joined Celldex in 2009 as Vice President, Clinical Development. Prior to that, she held several senior level roles at CuraGen Corporation, most recently serving as the Vice President of Development Operations, responsible for strategic and operational development activities of the oncology and oncology supportive care portfolio, regulatory affairs, clinical operations and data management. Ms. Crowley started her career at Bayer Corporation in 1992, holding various positions providing leadership of clinical research and project management prior to completing her tenure there as the Director of Global Study Audit Management, assuring the highest standards for program execution. Ms. Crowley received her BS in Chemistry with a concentration in Business from Boston College.